This webinar on Clinical Importance of Drug Resistance Mechanisms in Ovarian Cancer on June 14, 2021 marks the ending of the HERCULES EU project. The goal of HERCULES was to characterize high-grade serous ovarian cancer via single-cell analysis and to find effective drug combinations to overcome drug resistance.

In this final webinar we have an exciting key note talk from a leading expert on clinical trials in ovarian cancer, Dr Stéphanie Lheureux, MD, PhD, from Princess Margaret Cancer Centre, Toronto, Canada. This is followed by selected talks by the project researchers on the clinically relevant results and lessons learnt over the past 5 and a half years. See all talks on the programme page and how to register at the registration page.

Registration deadline has been extended until the beginning of the seminar, assuming the is still room in the webinar license.


HERCULES is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667403 for 2016-2021.

EU flag